Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis
Authors
Keywords
-
Journal
LABORATORY INVESTIGATION
Volume 95, Issue 5, Pages 525-533
Publisher
Springer Nature
Online
2015-03-02
DOI
10.1038/labinvest.2015.35
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
- (2014) Angelo Avogaro et al. DIABETES CARE
- Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
- (2014) S. Nakashima et al. HORMONE AND METABOLIC RESEARCH
- Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
- (2014) Yuliya Sharkovska et al. JOURNAL OF HYPERTENSION
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
- (2013) Yuji Ishibashi et al. Cardiovascular Diabetology
- DNA Aptamer Raised Against AGEs Blocks the Progression of Experimental Diabetic Nephropathy
- (2013) Yusuke Kaida et al. DIABETES
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression
- (2012) Ayako Ojima et al. AMERICAN JOURNAL OF PATHOLOGY
- Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans
- (2012) Nobuhiro Tahara et al. CLINICAL BIOCHEMISTRY
- Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
- (2012) Sho-ichi Yamagishi et al. CURRENT PHARMACEUTICAL DESIGN
- Glucose-dependent Insulinotropic Polypeptide (GIP) Inhibits Signaling Pathways of Advanced Glycation End Products (AGEs) in Endothelial Cells via its Antioxidative Properties
- (2012) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Sitagliptin Augments Protective Effects of GLP-1 against Advanced Glycation End Product Receptor Axis in Endothelial Cells
- (2011) Y. Ishibashi et al. HORMONE AND METABOLIC RESEARCH
- Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level
- (2011) Yuji Ishibashi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Advanced glycation end-products and the kidney
- (2010) Martin Busch et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-κB activation
- (2010) Yuichiro Ide et al. MICROVASCULAR RESEARCH
- Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy
- (2010) Sho-ichi Yamagishi et al. Oxidative Medicine and Cellular Longevity
- Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
- (2009) Yuji Ishibashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- On the origin of serum CD26 and its altered concentration in cancer patients
- (2009) Oscar J. Cordero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets
- (2009) Karly Sourris et al. CURRENT DRUG TARGETS
- Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy
- (2009) S. D. Ye et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- RAGE, glomerulosclerosis and proteinuria: Roles in podocytes and endothelial cells
- (2009) Vivette D’Agati et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes
- (2008) A. Soro-Paavonen et al. DIABETES
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search